Walleye Capital’s Reviva Pharmaceuticals Warrants RVPHW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-33,718
| Closed | -$4.55K | – | 5449 |
|
|
2024
Q3 | $4.55K | Hold |
33,718
| – | – | ﹤0.01% | 5001 |
|
|
2024
Q2 | $9.1K | Hold |
33,718
| – | – | ﹤0.01% | 5243 |
|
|
2024
Q1 | $21.3K | Hold |
33,718
| – | – | ﹤0.01% | 4909 |
|
|
2023
Q4 | $48.2K | Hold |
33,718
| – | – | ﹤0.01% | 4312 |
|
|
2023
Q3 | $51.9K | Hold |
33,718
| – | – | ﹤0.01% | 4185 |
|
|
2023
Q2 | $59.7K | Sell |
33,718
-20,598
| -38% | -$38.6K | ﹤0.01% | 3598 |
|
|
2023
Q1 | $54.3K | Hold |
54,316
| – | – | ﹤0.01% | 3182 |
|
|
2022
Q4 | $53.8K | Sell |
54,316
-35,307
| -39% | -$30.1K | ﹤0.01% | 2510 |
|
|
2022
Q3 | $17K | Hold |
89,623
| – | – | ﹤0.01% | 2746 |
|
|
2022
Q2 | $16K | Hold |
89,623
| – | – | ﹤0.01% | 1938 |
|
|
2022
Q1 | $24K | Hold |
89,623
| – | – | ﹤0.01% | 1928 |
|
|
2021
Q4 | $31K | Hold |
89,623
| – | – | ﹤0.01% | 1846 |
|
|
2021
Q3 | $36 | Hold |
89,623
| – | – | ﹤0.01% | 1431 |
|
|
2021
Q2 | $45 | Buy |
89,623
+24,664
| +38% | +$11.1K | ﹤0.01% | 1234 |
|
|
2021
Q1 | $30 | Hold |
64,959
| – | – | ﹤0.01% | 1102 |
|
|
2020
Q4 | $44 | Hold |
64,959
| – | – | ﹤0.01% | 882 |
|
|
2020
Q3 | $34K | Buy |
64,959
+1,458
| +2% | +$650 | ﹤0.01% | 772 |
|
|
2020
Q2 | $30K | Buy |
+63,501
| New | +$14.9K | 0.01% | 565 |
|
Other funds holding RVPHW
Walleye Capital's RVPHW Position: Q4 2024 in Review
Walleye Capital sold out of Reviva Pharmaceuticals Warrants (RVPHW) in Q4 2024, closing a stake of 33,718 shares — an estimated $4.55K sold.
Walleye Capital first reported a position in RVPHW in Q2 2020 and held it in 18 quarters. The position peaked at $59.7K in Q2 2023. 2 funds tracked by Wall St. Rank hold RVPHW as of Q4 2024.
- Walleye Capital reported no remaining Reviva Pharmaceuticals Warrants position as of Q4 2024 after selling out during the quarter.
- Walleye Capital sold 33,718 Reviva Pharmaceuticals Warrants shares in Q4 2024, an estimated $4.55K.
- Walleye Capital first reported a position in Reviva Pharmaceuticals Warrants in Q2 2020 and held it in 18 quarters.
- Walleye Capital's Reviva Pharmaceuticals Warrants position peaked at $59.7K in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reviva Pharmaceuticals Warrants as of Q4 2024.
Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.